Lucid Diagnostics (LUCD) Stock Forecast, Price Target & Predictions
LUCD Stock Forecast
Lucid Diagnostics stock forecast is as follows: an average price target of $2.87 (represents a 244.99% upside from LUCD’s last price of $0.83) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LUCD Price Target
The average price target for Lucid Diagnostics (LUCD) is $2.87 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $3.10 to $2.50. This represents a potential 244.99% upside from LUCD's last price of $0.83.
LUCD Analyst Ratings
According to 3 Wall Street analysts, Lucid Diagnostics's rating consensus is 'Buy'. The analyst rating breakdown for LUCD stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 0 'Hold' (0.00%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).
Lucid Diagnostics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Kyle Mikson | Canaccord Genuity | $3.00 | $0.95 | 215.79% | 260.62% |
| Apr 08, 2024 | Mark Massaro | BTIG | $2.50 | $0.93 | 169.48% | 200.52% |
| Nov 18, 2022 | - | BTIG | $3.50 | $1.91 | 83.25% | 320.72% |
| Nov 15, 2022 | - | Needham | $3.10 | $2.27 | 36.56% | 272.64% |
The latest Lucid Diagnostics stock forecast, released on May 14, 2024 by Kyle Mikson from Canaccord Genuity, set a price target of $3.00, which represents a 215.79% increase from the stock price at the time of the forecast ($0.95), and a 260.62% increase from LUCD last price ($0.83).
Lucid Diagnostics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $2.75 |
| Last Closing Price | $0.83 | $0.83 | $0.83 |
| Upside/Downside | -100.00% | -100.00% | 230.57% |
In the current month, the average price target of Lucid Diagnostics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lucid Diagnostics's last price of $0.83. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 08, 2024 | BTIG | Buy | Buy | Hold |
| Nov 18, 2022 | BTIG | Buy | Buy | Hold |
| Nov 15, 2022 | Needham | Buy | Buy | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Sell | Downgrade |
Lucid Diagnostics's last stock rating was published by BTIG on Apr 08, 2024. The company gave LUCD a "Buy" rating, the same as its previous rate.
Lucid Diagnostics Financial Forecast
Lucid Diagnostics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $1.04M | $783.00K | $159.00M | $446.00K | $112.00K | $76.00K | - | $189.00K | $300.00K | $200.00K |
| Avg Forecast | $11.25M | $17.33M | $8.78M | $6.63M | $3.97M | $2.86M | $2.33M | $1.78M | $1.36M | $1.14M | $1.22M | $1.05M | $1.04M | $799.67K | $620.00K | $238.78K | $341.74K | $431.38K | $630.41K | $462.86K | $390.88K | $54.50K |
| High Forecast | $12.14M | $18.71M | $9.48M | $7.16M | $4.28M | $3.09M | $2.52M | $1.93M | $1.46M | $1.23M | $1.32M | $1.13M | $1.29M | $863.36K | $669.38K | $257.80K | $368.96K | $465.73K | $630.41K | $591.63K | $499.62K | $69.66K |
| Low Forecast | $8.96M | $13.80M | $7.00M | $5.28M | $3.16M | $2.28M | $1.86M | $1.42M | $1.08M | $905.18K | $973.78K | $834.69K | $891.43K | $636.91K | $493.81K | $190.18K | $272.18K | $343.57K | $630.41K | $382.82K | $323.28K | $45.08K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.98% | 256.45% | 1.87% | 0.33% | 0.18% | - | 0.41% | 0.77% | 3.67% |
Lucid Diagnostics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.05M, with a low forecast of $834.69K, and a high forecast of $1.13M. LUCD's average Quarter revenue forecast represents a 0.77% increase compared to the company's last Quarter revenue of $1.04M (Dec 23).
Lucid Diagnostics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-10.82M | $-13.41M | $-11.58B | $-15.60M | $-14.31M | $-13.76M | - | $-12.07M | $-11.24M | $-6.51M |
| Avg Forecast | $-2.25M | $-3.47M | $-1.76M | $-1.33M | $-793.12K | $-571.89K | $-466.10K | $-356.67K | $-271.03K | $-227.30K | $-244.53K | $-209.60K | $-208.00K | $-159.93K | $-124.00K | $-47.76K | $-68.35K | $-86.27K | $-126.08K | $-92.57K | $-78.17K | $-3.82B |
| High Forecast | $-1.79M | $-2.76M | $-1.40M | $-1.06M | $-631.68K | $-455.49K | $-371.23K | $-284.07K | $-215.87K | $-181.03K | $-194.76K | $-166.94K | $-178.28K | $-127.38K | $-98.76K | $-38.03K | $-54.44K | $-68.71K | $-126.08K | $-76.56K | $-64.66K | $-3.05B |
| Low Forecast | $-2.43M | $-3.74M | $-1.90M | $-1.43M | $-856.28K | $-617.44K | $-503.23K | $-385.07K | $-292.62K | $-245.40K | $-264.00K | $-226.29K | $-257.52K | $-172.67K | $-133.88K | $-51.56K | $-73.79K | $-93.15K | $-126.08K | $-118.32K | $-99.92K | $-4.58B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 52.04% | 83.83% | 93420.11% | 326.71% | 209.42% | 159.45% | - | 130.42% | 143.78% | 0.00% |
undefined analysts predict LUCD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lucid Diagnostics's previous annual EBITDA (undefined) of $NaN.
Lucid Diagnostics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-10.83M | $-14.21M | $-11.38B | $-1.98B | $-14.76M | $-14.35M | - | $-12.44M | $-11.37M | $-7.40M |
| Avg Forecast | - | - | - | - | $-7.55M | $-7.71M | $-8.04M | $-8.20M | $-9.35M | $-8.08M | $-9.64M | $-11.57M | $-11.09M | $-11.45M | $-13.62M | $-15.68M | $-15.91M | $-16.93M | $-14.99M | $-10.98M | $-10.90M | $-3.59B |
| High Forecast | - | - | - | - | $-5.55M | $-5.67M | $-5.91M | $-6.03M | $-6.88M | $-7.02M | $-7.09M | $-8.51M | $-8.10M | $-8.42M | $-10.02M | $-11.53M | $-11.70M | $-12.45M | $-14.99M | $-8.51M | $-8.45M | $-2.87B |
| Low Forecast | - | - | - | - | $-8.34M | $-8.51M | $-8.87M | $-9.04M | $-10.32M | $-9.13M | $-10.64M | $-12.77M | $-12.79M | $-12.64M | $-15.03M | $-17.30M | $-17.56M | $-18.68M | $-14.99M | $-14.95M | $-14.84M | $-4.30B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.24% | 835.62% | 126.25% | 0.93% | 0.85% | - | 1.13% | 1.04% | 0.00% |
Lucid Diagnostics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LUCD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lucid Diagnostics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.49M | $8.16M | $7.86B | $10.64M | $10.47M | $9.59M | - | $9.04M | $7.62M | $4.38M |
| Avg Forecast | $355.82M | $548.26M | $277.88M | $209.81M | $125.46M | $90.47M | $73.73M | $56.42M | $42.87M | $35.96M | $38.68M | $33.16M | $32.90M | $25.30M | $19.62M | $7.55M | $10.81M | $13.65M | $19.94M | $14.64M | $12.37M | $1.72M |
| High Forecast | $384.16M | $591.92M | $300.01M | $226.52M | $135.45M | $97.67M | $79.60M | $60.91M | $46.29M | $38.82M | $41.76M | $35.80M | $40.74M | $27.31M | $21.18M | $8.16M | $11.67M | $14.73M | $19.94M | $18.72M | $15.81M | $2.20M |
| Low Forecast | $283.40M | $436.66M | $221.32M | $167.10M | $99.92M | $72.05M | $58.72M | $44.94M | $34.15M | $28.64M | $30.81M | $26.41M | $28.20M | $20.15M | $15.62M | $6.02M | $8.61M | $10.87M | $19.94M | $12.11M | $10.23M | $1.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.26% | 0.32% | 400.81% | 1.41% | 0.97% | 0.70% | - | 0.62% | 0.62% | 2.54% |
Lucid Diagnostics's average Quarter SG&A projection for Mar 24 is $33.16M, based on 3 Wall Street analysts, with a range of $26.41M to $35.80M. The forecast indicates a 290.57% rise compared to LUCD last annual SG&A of $8.49M (Dec 23).
Lucid Diagnostics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 2 | 1 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.26 | $-0.34 | $-272.05 | $-48.31 | $-0.41 | $-0.39 | - | $-0.35 | $-0.31 | $-0.20 |
| Avg Forecast | - | - | - | - | $-0.16 | $-0.16 | $-0.17 | $-0.17 | $-0.19 | $-0.17 | $-0.20 | $-0.24 | $-0.23 | $-0.24 | $-0.28 | $-0.33 | $-0.33 | $-0.35 | $-0.33 | $-0.26 | $-0.26 | $-0.29 |
| High Forecast | - | - | - | - | $-0.12 | $-0.12 | $-0.12 | $-0.13 | $-0.14 | $-0.15 | $-0.15 | $-0.18 | $-0.17 | $-0.17 | $-0.21 | $-0.24 | $-0.24 | $-0.26 | $-0.33 | $-0.20 | $-0.20 | $-0.22 |
| Low Forecast | - | - | - | - | $-0.17 | $-0.18 | $-0.18 | $-0.19 | $-0.21 | $-0.19 | $-0.22 | $-0.26 | $-0.27 | $-0.26 | $-0.31 | $-0.36 | $-0.36 | $-0.39 | $-0.33 | $-0.35 | $-0.35 | $-0.39 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.13% | 1.43% | 963.01% | 148.56% | 1.24% | 1.11% | - | 1.35% | 1.20% | 0.70% |
According to undefined Wall Street analysts, Lucid Diagnostics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LUCD previous annual EPS of $NaN (undefined).
Lucid Diagnostics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LUCD | Lucid Diagnostics | $0.83 | $2.87 | 245.78% | Buy |
| XAIR | Beyond Air | $0.40 | $1.00 | 150.00% | Buy |
| OFIX | Orthofix Medical | $16.14 | $31.00 | 92.07% | - |
| NPCE | NeuroPace | $6.82 | $12.88 | 88.86% | Buy |
| CVRX | CVRx | $8.69 | $15.83 | 82.16% | Buy |
| FNA | Paragon 28 | $6.96 | $11.50 | 65.23% | Buy |
| NARI | Inari Medical | $44.38 | $70.33 | 58.47% | Buy |
| LUNG | Pulmonx | $8.40 | $12.25 | 45.83% | Buy |
| LIVN | LivaNova | $51.07 | $70.20 | 37.46% | Buy |
| KIDS | OrthoPediatrics | $30.06 | $40.80 | 35.73% | Buy |
| IRMD | IRadimed | $48.45 | $60.00 | 23.84% | Buy |
| CLPT | ClearPoint Neuro | $11.66 | $12.00 | 2.92% | Buy |
| ITGR | Integer | $128.36 | $131.00 | 2.06% | Buy |
| SRDX | Surmodics | $39.30 | $39.50 | 0.51% | Buy |
LUCD Forecast FAQ
Is Lucid Diagnostics a good buy?
Yes, according to 3 Wall Street analysts, Lucid Diagnostics (LUCD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of LUCD's total ratings.
What is LUCD's price target?
Lucid Diagnostics (LUCD) average price target is $2.87 with a range of $2.5 to $3.1, implying a 244.99% from its last price of $0.832. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Lucid Diagnostics stock go up soon?
According to Wall Street analysts' prediction for LUCD stock, the company can go up by 244.99% (from the last price of $0.832 to the average price target of $2.87), up by 272.64% based on the highest stock price target, and up by 200.52% based on the lowest stock price target.
Can Lucid Diagnostics stock reach $1?
LUCD's average twelve months analyst stock price target of $2.87 supports the claim that Lucid Diagnostics can reach $1 in the near future.
What are Lucid Diagnostics's analysts' financial forecasts?
Lucid Diagnostics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $10.94M (high $11.81M, low $8.71M), average EBITDA is $-2.188M (high $-1.742M, low $-2.362M), average net income is $-31.499M (high $-23.164M, low $-34.76M), average SG&A $346.08M (high $373.64M, low $275.64M), and average EPS is $-0.653 (high $-0.48, low $-0.721). LUCD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $43.99M (high $47.49M, low $35.04M), average EBITDA is $-8.798M (high $-7.007M, low $-9.499M), average net income is $0 (high $0, low $0), average SG&A $1.39B (high $1.5B, low $1.11B), and average EPS is $0 (high $0, low $0).
Did the LUCD's actual financial results beat the analysts' financial forecasts?
Based on Lucid Diagnostics's last annual report (Dec 2023), the company's revenue was $2.43B, beating the average analysts forecast of $2.7M by 89877.45%. Apple's EBITDA was $-48.482B, beating the average prediction of $-540K by 8983255.17%. The company's net income was $-52.666B, beating the average estimation of $-51.837M by 101499.99%. Apple's SG&A was $35.66B, beating the average forecast of $85.37M by 41668.03%. Lastly, the company's EPS was $-1.261K, beating the average prediction of $-1.075 by 117208.73%. In terms of the last quarterly report (Dec 2023), Lucid Diagnostics's revenue was $1.04M, beating the average analysts' forecast of $1.04M by 0%. The company's EBITDA was $-10.824M, beating the average prediction of $-208K by 5103.87%. Lucid Diagnostics's net income was $-10.83M, missing the average estimation of $-11.089M by -2.33%. The company's SG&A was $8.49M, missing the average forecast of $32.9M by -74.20%. Lastly, the company's EPS was $-0.26, beating the average prediction of $-0.23 by 13.04%